Chemotherapy-Induced Diarrhea (CID) market | Size, Share, Growth

Chemotherapy-Induced Diarrhea (CID) market Research Report

Published: 2025 - January

Report Code: VMR-17741

Region: Global

Request Sample

Customization

Ask an Expert

Enquire Enquire Before Buying

Chemotherapy-Induced Diarrhea (CID) Market Analysis

The Chemotherapy-Induced Diarrhea (CID) market pertains to the global treatment landscape for diarrhea, which arises as a side effect of chemotherapy, a common cancer treatment. CID is a significant adverse event that can severely affect a patient's quality of life, leading to dehydration, malnutrition, and disruptions in treatment regimens. The market encompasses pharmaceuticals, therapies, and supportive care treatments aimed at mitigating the symptoms and improving patient outcomes during cancer therapy.

Disruptive Impact and Opportunities:

CID has become a critical focus for both oncologists and patients, with the growing demand for safer and more effective treatments. The market offers ample opportunities due to an increased prevalence of chemotherapy regimens and their side effects, presenting avenues for new drug development and better treatment strategies. The evolution towards easy-to-administer oral formulations and injectable options offers major benefits, improving patient compliance and convenience. Additionally, novel therapies targeting specific pathways in CID promise to enhance the safety profile of treatments and improve overall outcomes.

Chemotherapy-Induced Diarrhea (CID) Market Segmentation: Emerging Drugs

MYTESI (crofelemer)

Chemotherapy-Induced Diarrhea (CID) Market Segmentation: Marketed Drugs

Loperamide (Imodium)
Diphenoxylate - atropine sulfate
Kaopectate® II caplets
Maalox® anti-diarrheal caplets
Pepto® Diarrhea control

Key Companies:

Napo Pharmaceuticals (Jaguar Health)
Ralington Pharma LLP
Wellona Pharma
Kramer Laboratories
Novartis International AG
SANOFI
Procter & Gamble

Chemotherapy-Induced Diarrhea (CID) Market Segmentation: By Drug Type

- Anti-Diarrheal Agents:
  - Loperamide
  - Diphenoxylate/Atropine
- Somatostatin Analogs:
  - Octreotide
  - Lanreotide
- Anti-inflammatory Agents:
  - Sulfasalazine
  - Mesalamine
- Other Drugs:
  - Racecadotril
  - Bismuth Subsalicylate

Chemotherapy-Induced Diarrhea (CID) Market Segmentation: By Administration Type

- Oral:
  - Tablets
  - Capsules
- Injectable:
  - Subcutaneous
  - Intravenous
- Topical:
  - Creams and Ointments

What’s in It for You?

Uncover the latest treatment trends and emerging drugs with a focus on CID.
Gain insights into key players and their strategies within the CID treatment sector.
Identify high-growth opportunities in novel treatment options, such as MYTESI.
Learn about the evolving market dynamics and regulatory landscape for CID therapies.
Discover actionable insights to enhance market positioning and decision-making strategies for CID-focused product launches.

Chemotherapy induced diarrhea Market - Executive Summary
1. Introduction
2. Objectives
3. Key Findings
  1. Market Size 2022 & 2032: By Key Country (10MM)
  2. Global Market Size 2022 & 2032: By Key Segment
  3. Key Investments & Startup Analysis
4. Research Methodology
Understanding the Disease
1. Disease Overview
2. Classification
3. Signs and Symptoms
4. Risk Factors
5. Causes
6. Disease Biology & Digital Innovations
7. Stages & Staging System
8. Diagnostic Algorithm
9. Current Treatment Practices & Algorithm
10. Current Standard of Care and Treatment Gaps
11. Patient Demographics and Treatment Pathways
Guidelines
Unmet Needs
Epidemiology and Patient Population
1. Epidemiology Key Findings
2. Assumptions and Rationale: 10MM
3. Epidemiology Scenario: 10MM
4. U.S. Epidemiology Scenario
5. EU-5 Epidemiology
  1. U.K. Epidemiology Scenario
  2. Germany Epidemiology Scenario
  3. France Epidemiology Scenario
  4. Italy Epidemiology Scenario
  5. Spain Epidemiology Scenario
6. Japan Epidemiology Scenario
7. China Epidemiology Scenario
8. Australia Epidemiology Scenario
9. India Epidemiology Scenario
Real-world Data & Real-world Evidence
Drug Development Landscape
1. Existing Key Drug Candidate Profiles/ Marketed Therapies
2. Competitive Analysis and Differentiation
3. Overview of Similar/Competing Drugs in Clinical Trials
4. Future Trends and Emerging Drugs
Regulatory Strategy and Potential Challenges
1. Regulatory Pathways in Key Markets
2. Anticipated Regulatory Hurdles and Mitigation Strategies
3. Case Studies in Oncology Drug Regulation
4. Impact of Potential Changes to Regulatory Frameworkc
Commercial Landscape
1. Market Size & Growth Rates
2. Key Approvals & Anticipated Loss of Exclusivity
3. PESTLE & Porter’s Five Forces Analysis
4. Market Shares, Positioning/Ranking
5. Market Drivers
6. Identification of Threats
7. Digital Evolution in Commercialization
Market Segmentation
Pricing, Reimbursement, and Access
1. Competitive Pricing Analysis
2. Reimbursement Landscape and Challenges
3. Strategies for Market Access and Equity
4. Patient Spending/Expenditure Analysis
Future Trends, Disruptions, and Opportunities
1. Analysis of Emerging Trends
2. Technological Impact
3. Impact of Potential Market Disruptors
4. Opportunities for Future Development and Expansion
5. Considerations for Investment Opportunities
Global Market Dynamics
1. Regional Regulatory Disparities
2. Cross-Border Partnership Strategies
3. Global Supply Chain Dynamics
4. Case Studies: Success and Failure in Global Markets
5. Strategies for Global Expansion and Localization
Company Profiles

Download Sample

Full Name *

Job Title *

Company *

Email *

Phone *

Country *

Message

↻

The field with (*) is required.

Choose License Type

Excel Data Pack

2500

Single User

4250

Multi User

5250

Corporate User

6900